<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028093</url>
  </required_header>
  <id_info>
    <org_study_id>020065</org_study_id>
    <secondary_id>02-DK-0065</secondary_id>
    <nct_id>NCT00028093</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease</brief_title>
  <official_title>Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of pegylated interferon, or peginterferon (a
      long-acting form of alpha interferon) plus ribavirin in treating hepatitis C (genotype 1)
      infection with and without kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 105 patients with chronic hepatitis C will be enrolled in a study of the combination of
      pegylated alpha interferon and ribavirin for 48 weeks with the option of early
      discontinuation of therapy for patients who do not respond within 24 weeks of starting
      therapy. Adult patients will be chosen who have chronic hepatitis C, HCV RNA in serum, HCV
      genotype 1 and liver histology showing chronic hepatitis C. Patients with advanced liver
      disease and clinical decompensation and patients who have received alpha interferon in the
      past will not be eligible. The 100 patients will consist of four groups: Groups A, B and D
      will comprise 25 patients each with typical uncomplicated chronic hepatitis C; Group C will
      comprise 25 patients with renal insufficiency or renal failure on chronic dialysis awaiting
      kidney transplantation. Group D will comprise up to 30 patients with typical uncomplicated
      chronic hepatitis C. After medical evaluation and liver biopsy, patients will begin receiving
      pegylated alpha interferon (peginterferon) by subcutaneous injection in a dose of 180 mcg per
      week. After the initial injection, patients will have blood taken and symptoms recorded at
      12, 24, 48, 72 hours and weekly thereafter for four weeks. Patients in Groups A, B and C will
      receive peginterferon weekly, whereas patients in Group D will receive it twice weekly in a
      reduced dose (90 mcg per injection) for the first 4 weeks of treatment and weekly in a dose
      of 180 mcg per injection thereafter. Patients in Groups A and D will also begin receiving
      ribavirin orally in a dose of 1000 mg (if body weight is less than 75 kg) or 1200 mg daily
      (if body weight greater than or equal to 75 kg) given in capsules of 200 mg twice daily
      starting with the first dose of peginterferon. Patients in Group B will start ribavirin in
      the doses given above after the first month of therapy (with the fifth injection: week 4).
      Patients in Group C (renal disease) will start ribavirin in a dose of 200 mg daily after the
      first month (week 4) of therapy; in this group the dose of ribavirin will be gradually
      increased at 4 week intervals on the basis of tolerance (hemolysis and anemia). During the
      initial 24-week period of combination therapy, patients will be seen in the outpatient clinic
      for medical interview, physical examinations and blood tests at 2 to 4 week intervals. At 24
      weeks, patients will be classified as either responders or non-responders based upon HCV RNA
      testing. Both groups will be offered therapy for another 24 weeks (total treatment = 48
      weeks). Because sustained responses are rare in patients who have not become HCV RNA negative
      by 24 weeks, non-responders will be offered the option of stopping therapy early and being
      followed on no therapy. After stopping therapy, patients will be followed at 1 to 2 month
      intervals and undergo repeat medical evaluation (without liver biopsy) at the 72 week point
      (18 months after enrollment).

      The primary criterion for success of therapy overall will be sustained loss of HCV RNA as
      assessed at 18 months. Secondary criteria will be normalization of ALT levels and improvement
      of symptoms. This study will allow for therapy of patients with chronic hepatitis C with the
      combination of peginterferon and ribavirin demonstrating whether early viral kinetics are
      predictive of outcome of therapy. This study will also allow for comparison of the kinetics
      of loss of HCV RNA comparing peginterferon alone to peginterferon with ribavirin,
      peginterferon given once weekly to peginterferon given twice weekly, and comparing kinetics
      between patients with and without renal disease. The study will also allow for assessment of
      the safety of addition of ribavirin in patients with renal compromise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatitis C Virus RNA Levels During Phase I</measure>
    <time_frame>From day 0 to day 3</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Pefinterferon+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients &lt;75 kg and 1200 mg daily for patients &gt;=75 kg) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a with Ribavirin</intervention_name>
    <description>Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients &lt;75 kg and 1200 mg daily for patients &gt;=75 kg) for 48 weeks</description>
    <arm_group_label>Pefinterferon+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.</description>
    <arm_group_label>Peginterferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        All Patients:

          -  Age 18 years or above, male or female.

          -  Presence of HCV RNA (with or without anti-HCV) in serum.

          -  Genotype 1 HCV as determined by probe specific hybridization (Inno-Lipa assay).

          -  Evidence of chronic hepatitis on liver biopsy done within the previous 48 months with
             a necroinflammatory histology activity index of at least 3 (out of a maximum of 18).

          -  Written informed consent.

        Additional inclusion criteria for Groups A, B and D:

        - Serum alanine (ALT) or aspartate aminotransferase (AST) above the upper limit of the
        normal range (ALT 41 greater than IU/L: AST greater than 31 IU/L) on any serum testing
        during the previous six months.

        Additional inclusion criteria for Group C:

          -  Chronic renal disease with creatinine clearance less than 50 cc/min or serum
             creatinine greater than 2.0 mg%.

          -  If on chronic hemodialysis or peritoneal dialysis, stable clinical condition including
             stable hematocrit.

          -  If on chronic dialysis, potential candidacy for renal transplantation.

        EXCLUSION CRITERIA:

          -  Previous treatment with alpha interferon.

          -  If cirrhosis is present, decompensated liver disease, as marked by bilirubin greater
             than 4 mg%, albumin less than 3.0 gm%, prothrombin time greater than 2 sec prolonged,
             or history of bleeding esophageal varices, ascites or hepatic encephalopathy.

          -  Serum ALT or AST levels greater than 1000 U/L (greater than 25 times ULN). Such
             patients will not be enrolled but may be followed until three determinations are below
             this level.

          -  Pregnancy or, in women of child-bearing potential or in spouses of such women,
             inability to practice adequate contraception, defined as vasectomy in men, tubal
             ligation in women, or use of condoms and spermicide, or birth control pills, or an
             intrauterine device.

          -  Significant systemic or major illnesses other than renal failure (in Group C),
             including congestive heart failure, organ transplantation, serious psychiatric disease
             or depression, human immunodeficiency virus (HIV) infection, and angina pectoris.

          -  Pre-existing anemia (hematocrit less than 33%) or known history of hemolytic anemia.
             In patients in Group C, erythropoetin therapy will be modified to achieve an adequate
             hematocrit if clinically indicated.

          -  Other antiviral therapy within the last 6 months.

          -  Immunosuppressive therapy with either corticosteroids (more than 5 mg of prednisone
             daily) or major immunosuppressive agents (such as azathioprine or 6-mercaptopurine).

          -  Evidence of another form of liver disease in addition to viral hepatitis (for example
             autoimmune liver disease, Wilson's disease, alcoholic liver disease, hemochromatosis,
             alpha-1-antitrypsin deficiency).

          -  Evidence of coronary artery disease or cerebral vascular disease, including
             abnormalities on exercise stress testing in patients with defined risk factors who
             will be screened for evidence of underlying coronary artery disease.

          -  Active substance abuse, such as alcohol, inhaled or injection drugs within the
             previous year.

          -  Evidence of hepatocellular carcinoma; either alphafetoprotein (AFP) levels greater
             than 50 ng/ml (normal less than 9 ng/ml) and/or ultrasound (or other imaging study)
             demonstrating a mass suggestive of liver cancer.

          -  Clinical gout.

          -  Active, serious autoimmune disease such as lupus erythematosis, ulcerative colitis,
             Crohn's disease or rheumatoid arthritis that in the opinion of the investigators might
             be exacerbated by therapy with alpha interferon.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Rotman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-DK-0065.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000 Feb 15;132(4):296-305. Review.</citation>
    <PMID>10681285</PMID>
  </reference>
  <reference>
    <citation>Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology. 1997 Jun;25(6):1527-38. Review.</citation>
    <PMID>9185778</PMID>
  </reference>
  <reference>
    <citation>Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990 Oct;12(4 Pt 1):671-5.</citation>
    <PMID>2170265</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2001</study_first_submitted>
  <study_first_submitted_qc>December 11, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2001</study_first_posted>
  <results_first_submitted>May 26, 2011</results_first_submitted>
  <results_first_submitted_qc>September 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2013</results_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Yaron Rotman, M.D.</investigator_full_name>
    <investigator_title>Asst. Clinical Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hemolysis</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Alpha Interferon</keyword>
  <keyword>Peginterferon</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Viral Hepatitis</keyword>
  <keyword>Hemolytic Anemia</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>Renal Dialysis</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon+Ribavirin</title>
          <description>peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients less than 75 kg and 1200 mg daily for patients greater than 75 kg) for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon Alone</title>
          <description>peginterferon-alpha 2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon+Ribavirin</title>
          <description>peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients less than 75 kg and 1200 mg daily for patients greater than 75 kg) for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon Alone</title>
          <description>peginterferon-alpha 2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="35" upper_limit="68"/>
                    <measurement group_id="B2" value="52" lower_limit="28" upper_limit="67"/>
                    <measurement group_id="B3" value="51" lower_limit="28" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of infection</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="9.0"/>
                    <measurement group_id="B2" value="23" spread="7.7"/>
                    <measurement group_id="B3" value="23" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mode of infection</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Injection drug use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.1" spread="17"/>
                    <measurement group_id="B2" value="76.8" spread="19"/>
                    <measurement group_id="B3" value="77.5" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/(m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="4.9"/>
                    <measurement group_id="B2" value="27.0" spread="4.8"/>
                    <measurement group_id="B3" value="27.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine transaminase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="61"/>
                    <measurement group_id="B2" value="96" spread="79"/>
                    <measurement group_id="B3" value="83" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ishak fibrosis</title>
          <description>Fibrosis was staged with the Ishak scale (ranging from 0 = no fibrosis to 6 = cirrhosis). Higher values represent a worse outcome.</description>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology activity index</title>
          <description>Possible range 0-18. Higher values represent a worse outcome.</description>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="5" upper_limit="13"/>
                    <measurement group_id="B2" value="8" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="B3" value="8" lower_limit="3" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C Virus RNA level</title>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="0.53"/>
                    <measurement group_id="B2" value="6.2" spread="0.58"/>
                    <measurement group_id="B3" value="6.2" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatitis C Virus RNA Levels During Phase I</title>
        <time_frame>From day 0 to day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon+Ribavirin</title>
          </group>
          <group group_id="O2">
            <title>Peginterferon</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatitis C Virus RNA Levels During Phase I</title>
          <units>log(IU/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="-0.40" upper_limit="2.30"/>
                    <measurement group_id="O2" value="0.70" lower_limit="-0.10" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the outcome between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon+Ribavirin</title>
          <description>peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients less than 75 kg and 1200 mg daily for patients greater than 75 kg) for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Peginterferon Alone</title>
          <description>peginterferon-alpha 2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C W</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</organization>
      <phone>3014961333</phone>
      <email>hoofnaglej@extra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

